New Bifunctional Chelator 3p-C-NEPA for Potential Applications in Lu(III) and Y(III) Radionuclide Therapy and Imaging
Sign Up to like & getrecommendations! Published in 2020 at "ACS Omega"
DOI: 10.1021/acsomega.0c03551
Abstract: We have developed structurally unique bifunctional chelators in the NETA, NE3TA, and DEPA series for potential radiopharmaceutical applications. As part of our continued research efforts to generate efficient bifunctional chelators for targeted radionuclide therapy and… read more here.
Keywords: chelator nepa; 90y 177lu; iii iii; chelator ... See more keywords
Optimized cocktail of 90Y/177Lu for radionuclide therapy of neuroendocrine tumors of various sizes: a simulation study
Sign Up to like & getrecommendations! Published in 2022 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001546
Abstract: Background and objectives There is significant interest and potential in the treatment of neuroendocrine tumors via peptide receptor radionuclide therapy (PRRT) using one or both of 90Y and 177Lu-labeled peptides. Given the presence of different… read more here.
Keywords: dose; 90y 177lu; neuroendocrine tumors; radionuclide therapy ... See more keywords
Abstract 2828: Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2828
Abstract: Background: Sequencing of immune checkpoint inhibitors (ICI) and external beam radiation therapy (EBRT) for cancer treatment has been studied, but the optimal sequencing has yet to be determined. While some studies have noted therapeutic advantages… read more here.
Keywords: sequencing immune; therapy; 90y 177lu; targeted radionuclide ... See more keywords